Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a primary brain tumour, such as gliomas (slow- or fast-growing), meningiomas inside the brain, pituitary adenomas, craniopharyngiomas, or other rare brain tumours
- People whose brain tumour has come back and who have not previously had radiation treatment
- People whose brain tumour has come back in an area that previously received a significant dose of radiation (more than 40 Gy)
- People for whom a doctor has recommended radiation therapy, either alone or combined with chemotherapy
- People for whom both proton therapy and standard radiation therapy (photons) are considered medically appropriate options (i.e., neither is the only obvious choice)
- People aged 18 or older
- People who are in reasonably good general health and are able to be treated as an outpatient (based on a standard medical fitness scale called ECOG, with a score of 2 or below)
- People recommended for high-dose radiation or combined radiation and chemotherapy (except those in a specific group within the trial called Group 4)
- People who are able to give informed consent and have provided it in writing
Who may not be able to join:
- People who are not able to give informed consent, or who have not provided written consent
- People with a type of brain cancer called cerebral lymphoma
- People whose brain tumours are metastases (cancers that have spread to the brain from elsewhere in the body)
- People with very small tumours (for example, acoustic neuromas or very small returning tumours) where proton therapy is not considered a medical alternative to a specific type of focused radiation called stereotactic radiotherapy
- People who are unable to have MRI scans used for treatment planning (for example, due to a medical reason that makes MRI unsafe for them)
- People who are unlikely to be able to follow the requirements of the trial (confirm with trial site)
- People who cannot be positioned in a consistent, reproducible way for treatment — for example, due to significant difficulties with movement or mobility
- People who are unable to attend regular follow-up appointments as required by the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mechthild Krause, Prof., University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology, German Consortium for Translational Cancer Research (DKTK)
Phone: +49 351 458 5441
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
late toxicity as cumulative measure
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.